Urolithin A vs NMN: Different Mechanisms, Which One First?
Start with urolithin A if your goal is muscle endurance or strength after 40; start with NMN if you want the cheaper, faster-to-measure lever on NAD+. They work on different parts of the mitochondrion, no trial has ever compared them head to head, and the honest default for most people is one at a time, not both at once.
The verdict
For most people: choose by complaint. Legs that tire sooner, or strength that has slipped since you turned 40: start with urolithin A. A measurable, lower-cost lever on cellular energy: start with NMN.
Where the other wins: urolithin A has never been shown to raise NAD+ in people, and NMN has yet to show a convincing strength gain against placebo. Each is weakest where the other is strongest.
The fact that decides it: urolithin A triggers mitophagy, the recycling of worn-out mitochondria. NMN restocks NAD+, the coenzyme those mitochondria burn to make energy. Same organelle, different lever.
Urolithin A and NMN get sold to the same person for the same reason, aging mitochondria, and they do almost nothing alike. Urolithin A is a postbiotic, a compound your gut bacteria are supposed to make from the ellagitannins in pomegranate and walnuts, and its one well-documented job in humans is switching on mitophagy. NMN (nicotinamide mononucleotide) is a direct precursor to NAD+, the coenzyme every cell spends to turn food into energy. One is a quality-control signal; the other is raw material.
No human trial has ever compared them. A PubMed search on October 14, 2026 for every paper mentioning both compounds returned six, and none was a comparison: a trial protocol, a mouse study of a drug candidate, two mechanism papers in cells and worms, a review, and one paper that bought commercial urolithin A and NMN capsules and tested them against their labels. That last one is the surprise of this page. Sandalova and colleagues (2024, GeroScience) found active-ingredient content from 28.6% over the label claim to 100% under it. Some capsules contained none of what the label promised. Whichever molecule you pick, the lot-specific certificate of analysis matters as much as the choice.
Side-by-side
| Urolithin A | NMN | |
|---|---|---|
| What it is | A postbiotic that gut bacteria make from ellagitannins in pomegranate, walnuts, and berries. You do not eat urolithin A; it is not in any food. | A nucleotide one enzymatic step from NAD+. Found in edamame, broccoli, and meat at about 1 mg per 100 g, far below any supplemental dose. |
| How it works | Activates mitophagy, the tagging and recycling of damaged mitochondria | Converted to NAD+ in the salvage pathway; raises whole-blood NAD+ within two to four weeks |
| Evidence grade (human) | Moderate for muscle endurance and strength after 40 (two placebo-controlled RCTs, both run by the ingredient's maker). Preliminary and mixed in trained athletes. | Strong for raising blood NAD+ (four RCTs, same direction every time). Moderate for six-minute walk distance (one 80-person RCT). Preliminary for strength, insulin sensitivity, and sleep. |
| Studied dose range | 500 to 1,000 mg daily; both doses moved muscle mitochondrial gene expression in the first-in-human trial | 250 to 1,250 mg daily; 600 mg gave the best NAD+ and walking results in the 80-person dose-ranging trial |
| Time to effect | Muscle endurance at 2 months, strength at 4 months | Blood NAD+ at 2 to 4 weeks; walking distance and self-rated health at 30 to 60 days |
| Typical cost per studied day | $1.50 at 500 mg; $3.00 at 1,000 mg (Mt. Angel Vitamins, October 14, 2026) | $1.00 at 250 mg; $2.00 at 500 mg, in a capsule that also carries NR (Mt. Angel Vitamins, October 14, 2026) |
| Safety notes | 1,000 mg daily for 4 months in adults 65 to 90: adverse events no different from placebo (Liu 2022) | 1,250 mg daily for 4 weeks in 31 adults (Fukamizu 2022, Scientific Reports) and 900 mg for 60 days (Yi 2023): no safety signal. Longest trials run 12 to 24 weeks. |
| Best for | Muscle endurance and strength after 40; a trial-matched dose aimed at a physical outcome | A measurable NAD+ response at low cost; general cellular energy support rather than one muscle outcome |
Where they actually differ
Mitophagy is housekeeping. Every cell carries hundreds to thousands of mitochondria, and the damaged ones leak reactive oxygen and make less ATP per unit of fuel. Mitophagy tags the failing ones and digests them so the cell can build replacements. It slows with age. Urolithin A is the best-documented dietary activator of it (D'Amico et al., 2021, Trends in Molecular Medicine). In the 2019 first-in-human trial (Andreux et al., Nature Metabolism), four weeks at 500 or 1,000 mg shifted skeletal-muscle gene expression toward mitochondrial programs and lowered plasma acylcarnitines, a marker of inefficient fat burning, in sedentary older adults. Urolithin A adds nothing to the cell; it tells the cell to clean house.
NAD+ is the currency. Nicotinamide adenine dinucleotide shuttles electrons in the reactions that turn glucose and fat into ATP, and sirtuins and PARP enzymes, the proteins that handle DNA repair and stress signaling, consume it as a substrate. Tissue NAD+ falls with age in rodents and in humans (Covarrubias et al., 2021, Nature Reviews Molecular Cell Biology). NMN is one enzymatic step from NAD+ in the salvage pathway, and oral NMN raises whole-blood NAD+ within weeks in every trial that measured it, including 250 mg a day for 12 weeks in 30 healthy adults (Okabe et al., 2022, Frontiers in Nutrition). It cleans nothing. It restocks the shelf.
The two can look similar from the outside because both show up in trials as better muscle performance. The route is different. Urolithin A improved muscle endurance in older adults without raising ATP production in the hand muscle where it was measured (Liu et al., 2022), which fits better-quality mitochondria rather than more fuel. NMN raised a fuel-side marker, blood NAD+, and improved walking distance (Yi et al., 2023) with no measured change in mitochondrial turnover. Urolithin A upgrades the engines. NMN tops off the tank. Neither has been shown in humans to do the other's job.
At the shelf, one more difference. Urolithin A has one human dose range that worked and one mechanism. NMN sits inside a crowded family of NAD+ precursors, including nicotinamide riboside (NR) and plain niacin, that all raise blood NAD+. Our NMN vs NR comparison covers that fork. Urolithin A has no equivalent debate.
What the trials say
Head to head: none. As of October 14, 2026, no randomized trial has given urolithin A to one group and NMN to another, and none has tested the combination. The one study that prescribed both, the PROMETHEUS feasibility protocol (Kuerec et al., 2026, GeroScience), assigned each to different participants by baseline muscle, fitness, and cognition. Personalization, not comparison. Everything below is each molecule against placebo.
Urolithin A
Singh et al., 2022, Cell Reports Medicine (randomized controlled trial). Middle-aged adults, 4 months, 500 or 1,000 mg daily of Mitopure urolithin A. Muscle strength rose about 12% versus placebo, with clinically meaningful gains in peak oxygen uptake and six-minute walk distance; the pre-registered primary endpoint, peak power output, did not reach significance. Plasma acylcarnitines and C-reactive protein fell. Limitation: run and analyzed by the ingredient's manufacturer, and the headline result is a secondary endpoint. Grade for strength: Moderate. See also why 1,000 mg is not twice as good as 500 mg.
Liu et al., 2022, JAMA Network Open (randomized controlled trial). 66 adults aged 65 to 90, 4 months, 1,000 mg daily. Muscle endurance (contractions to fatigue in a hand and a leg muscle) beat placebo at 2 months. The co-primary endpoints, six-minute walk distance and maximal ATP production in hand muscle, improved in both arms with no significant difference between them. Adverse events matched placebo, and the limitation is the sample: 76% women, all white, both primary endpoints missed. Grade for endurance: Moderate; for walk distance: Insufficient.
Zhao et al., 2024, Journal of the International Society of Sports Nutrition (randomized controlled trial). 20 resistance-trained men, 8 weeks, 1 g daily. Isometric strength and repetitions to failure improved versus placebo; one-rep-max bench press and squat did not reach significance. Limitation: ten per arm. Grade: Preliminary.
Whitfield et al., 2025, Sports Medicine (randomized controlled trial). 42 highly trained male distance runners, 4 weeks, 1,000 mg daily at altitude. No improvement in 3,000 m time-trial performance. Perceived exertion and creatine kinase after the time trial were lower than placebo, and muscle proteomics showed mitochondrial pathways up and inflammatory pathways down. Limitation: elite population, four weeks, manufacturer co-authors. Grade for performance: Insufficient; recovery markers: Preliminary.
NMN
Yi et al., 2023, GeroScience (randomized controlled trial). 80 healthy middle-aged adults, 60 days, placebo or 300, 600, or 900 mg daily. Blood NAD+ rose in every NMN group by day 30. Six-minute walk distance improved versus placebo at all three doses, most at 600 and 900 mg. Insulin resistance (HOMA-IR) did not change. Limitation: soft secondary endpoints and industry-affiliated authors. Grade for NAD+: Strong, with the other NAD+ trials; for walk distance: Moderate.
Igarashi et al., 2022, npj Aging (randomized controlled trial). 42 men aged 65 and older, 250 mg daily or placebo for 12 weeks; a supplier error meant only 20 finished on the right capsules. Whole-blood NAD+ rose. Gait speed and left-hand grip improved nominally; muscle mass, visceral fat, and insulin sensitivity did not change. Limitation: the dropout halved the sample. Grade for strength: Preliminary.
Yoshino et al., 2021, Science (randomized controlled trial). 25 postmenopausal women with prediabetes who were overweight or obese, 10 weeks, 250 mg daily. Insulin-stimulated glucose disposal and muscle insulin signaling improved; placebo did not. Limitation: one small trial in one metabolic phenotype, and Igarashi found no insulin effect in healthy men. Grade: Preliminary.
Liao et al., 2021, Journal of the International Society of Sports Nutrition (randomized controlled trial). 48 amateur runners, 6 weeks of training plus placebo or 300, 600, or 1,200 mg daily. Power at both ventilatory thresholds rose more at 600 and 1,200 mg than on placebo; VO2max did not. Limitation: twelve per arm. Grade: Preliminary.
Kim et al., 2022, Nutrients (randomized controlled trial). 108 older Japanese adults, 12 weeks, 250 mg in the morning or afternoon against matched placebos. Afternoon NMN produced the largest gain in five-times sit-to-stand and the largest drop in drowsiness. Limitation: moderate effects; the timing finding is exploratory. Grade: Preliminary.
What has not been tested. No placebo-controlled trial of either compound has run beyond six months. None has measured lifespan, whether urolithin A changes NAD+ in people, or whether NMN changes mitophagy in human muscle. The combination has never been studied. Overlap is plausible, since NAD+ feeds the sirtuins that help regulate mitochondrial turnover, but plausible is not demonstrated. The full record on each is in the complete urolithin A guide and the NAD+ and longevity guide.
Who should pick which
If your complaint is muscle endurance or strength after 40
Urolithin A. The two largest trials (Singh 2022, Liu 2022) were built around those endpoints at 500 to 1,000 mg, and both found gains within two to four months. NMN's muscle data is gait speed and chair-stand time from small or exploratory analyses.
If you want a measurable result at the lowest cost
NMN. Blood NAD+ rises within two to four weeks at 250 mg, about a dollar a day, and a whole-blood NAD+ test can confirm it. Urolithin A has no marker a consumer can check.
If you are a trained athlete
Neither wins cleanly. At 1,000 mg a day, urolithin A lowered post-race muscle damage markers and perceived exertion in trained runners without improving race time; at 600 to 1,200 mg, NMN raised amateur runners' ventilatory thresholds without raising VO2max. If recovery is the goal, urolithin A. If aerobic adaptation is the goal, NMN, with modest expectations either way.
If you are over 65
Urolithin A, with a caveat. Liu 2022 is the only trial of either compound to enroll adults 65 to 90 and beat placebo on a muscle outcome. NMN's trials in this age group (Igarashi, Kim) found nominal gait and sit-to-stand gains at 250 mg. NMN at $1.00 is the fallback when $3.00 is too much.
If you want both
Nobody has tested the combination, so there is no evidence for it and no safety data against it. The mechanisms do not compete. The sensible sequence is one at a time: start with the pick above, hold it 8 to 12 weeks, judge it, then add the second. Running both from day one costs $2.50 to $5.00 a day and leaves you unable to tell which one did what.
Cost per effective day
Prices were read from the Mt. Angel Vitamins product pages on October 14, 2026. Both bottles hold 60 capsules. Our urolithin A buying guide and NMN and NR buying guide run the same math for competitor products.
| Product | Price | Dose per day | Days per bottle | Cost per day |
|---|---|---|---|---|
| Urolithin A 500 mg (Mt. Angel Vitamins) | $89.99 | 500 mg (1 capsule) | 60 | $1.50 |
| Urolithin A 500 mg (Mt. Angel Vitamins) | $89.99 | 1,000 mg (2 capsules) | 30 | $3.00 |
| NMN + NR Cellular Wellness (Mt. Angel Vitamins) | $59.99 | 250 mg NMN + 100 mg NR (1 capsule) | 60 | $1.00 |
| NMN + NR Cellular Wellness (Mt. Angel Vitamins) | $59.99 | 500 mg NMN + 200 mg NR (2 capsules) | 30 | $2.00 |
Urolithin A costs more per studied day, and that is the molecule, not the brand: the trial doses are two to four times higher in milligrams and the raw material costs more to make. Matching the 600 mg that performed best in Yi 2023 takes two to three NMN capsules, $2.00 to $3.00, which closes most of the gap. The NMN row is a combination product, so the dollar also buys 250 mg of resveratrol, 50 mg of TMG, and 10 mg of zinc; the evidence behind each ingredient in that stack is its own page. A 15% subscription discount puts 500 mg of urolithin A at $1.27 a day and 250 mg of NMN at 85 cents.
A note on our products
We make both products in the table above, in our own cGMP facility in Mt. Angel, Oregon, and we have an interest in which one you choose. Our Urolithin A 500 mg delivers the lower trial dose in one capsule and supports mitochondrial renewal and muscle endurance. Our NMN + NR Cellular Wellness pairs 500 mg of NMN with 200 mg of NR, plus resveratrol, TMG, and zinc, to support healthy NAD+ levels and cellular energy. Every batch is tested in our in-house lab for identity, potency, and purity, and each lot's certificate of analysis is published on our lab-testing page. Given the 2024 label-testing results, read that certificate before anything else on the bottle.
Next reads
- How urolithin A triggers mitophagy, down to the cell: the mechanism piece, for readers who want the pathway, not just the trials.
- NMN vs NR: which NAD+ precursor should you take?: if you landed on NMN, this is the next fork.
- The best urolithin A supplements, ranked: five picks at today's prices, one of them ours.
The Bottom Line
Pick by complaint, not by hype. Muscle endurance or strength slipping after 40: urolithin A, 500 to 1,000 mg a day, judged at four months. A measurable NAD+ lever for about a dollar a day: NMN, 250 to 600 mg, judged at eight weeks. No trial has compared them, so start with one, give it a fair run of eight to sixteen weeks, and add the other only if you still want to.
Related Products
FAQ
What does urolithin A do that NMN does not?
Urolithin A activates mitophagy, the process cells use to tag and recycle damaged mitochondria, and in the 2019 first-in-human trial (Andreux et al., Nature Metabolism) four weeks of it shifted muscle gene expression toward mitochondrial programs in sedentary older adults. NMN has never been shown to change mitophagy in people. The reverse is also true: NMN raises whole-blood NAD+ within weeks in every trial that measured it, and urolithin A has never been shown to raise NAD+ in humans. One cleans out worn mitochondria; the other restocks the coenzyme they run on.
Which has the stronger human trial record, urolithin A or NMN?
It depends on what you count. NMN has more randomized trials, at least eight placebo-controlled studies since 2021, and the most consistent result in the field: blood NAD+ goes up every time. Urolithin A has fewer trials but the two largest (Singh 2022 in middle-aged adults, Liu 2022 in adults 65 to 90) ran four months and measured strength and endurance directly, which NMN's trials mostly have not. For a biomarker, NMN wins. For a physical outcome, urolithin A does.
Can you take urolithin A and NMN together?
No trial has tested the combination, so there is no evidence it helps and no safety data saying it hurts. The mechanisms do not compete. One triggers mitochondrial recycling; the other supplies an NAD+ precursor. The practical problem with starting both at once is that you cannot tell which one did what. A sensible sequence is to start the one that matches your goal, hold it for 8 to 12 weeks, judge it, and only then add the second. Talk to your clinician first if you take prescription medication.
Which one is better for muscle endurance?
Urolithin A, on current evidence. In a 2022 randomized trial of 66 adults aged 65 to 90 (Liu et al., JAMA Network Open), 1,000 mg a day improved muscle endurance, measured as contractions to fatigue, at two months. A second trial in middle-aged adults (Singh et al., 2022, Cell Reports Medicine) found about 12% higher muscle strength at four months. NMN's closest result is longer six-minute walk distance in an 80-person, 60-day trial (Yi et al., 2023), which is a walking-capacity outcome rather than a muscle endurance test.
Which one is better for cellular energy and NAD+?
NMN. It is one enzymatic step from NAD+, and oral doses of 250 to 1,250 mg raised whole-blood NAD+ in every placebo-controlled trial that measured it, usually within two to four weeks (Okabe 2022, Igarashi 2022, Yi 2023). Urolithin A has never been shown to raise NAD+ in humans; its contribution to cellular energy runs through mitochondrial quality, not coenzyme supply. If the number you want to move is NAD+, pick NMN. If the result you want is muscle that lasts longer, read the endurance answer above.
Is there any trial that compares urolithin A and NMN head to head?
No. As of October 14, 2026, a PubMed search for every paper mentioning both compounds returned six results and none was a comparison trial: a feasibility protocol that prescribes each to different participants based on their baseline fitness profile, a mouse study of a multi-ingredient drug candidate, two laboratory mechanism papers, a review of sirtuin activators, and a 2024 study that tested commercial capsules against their label claims. Every verdict on this page comes from placebo-controlled trials of each compound on its own.
Does the brand or form matter for urolithin A and NMN?
More than for most supplements. In 2024, Sandalova and colleagues (GeroScience) bought urolithin A and NMN products online and in pharmacies and measured the active ingredient. Results ranged from 28.6% above the label claim to 100% below it, meaning some capsules contained none. The Amazentis-run urolithin A trials used that company's own material, sold as Mitopure; other brands sell the same molecule, but you are relying on their testing. For either compound, look for a lot-specific certificate of analysis from an independent lab, not a generic quality badge.